下載電子全文宣告This thesis is authorized to indicate not accessible
You can not download at the moment.
Your IP address is 220.127.116.11
The defense date of the thesis is 2015-08-18
The current date is 2019-04-21
This thesis will be accessible at off-campus not accessible
URN etd-0816115-234738 Statistics This thesis had been viewed 670 times. Download 0 times. Author Ching-yi Chiu Author's Email Address No Public. Department Bioengineering Year 2014 Semester 2 Degree Master Type of Document Master's Thesis Language zh-TW.Big5 Chinese Page Count 67 Title The Analysis of Biological Specimens by Liquid Chromatography with Tandem Mass Spectrometry Keyword Plasma Mass spectrometry Liquid chromatography Liquid chromatography Mass spectrometry Plasma Abstract This work was aimed to analyze the concentration of anti-cancer drug Irinotecan and its metabolite in the blood plasma using liquid chromatography mass spectrometry. A pretreatment step and a quantitative validation method for the two different compounds were developed, respectively.
Samples were spiked with internal standard, processed by protein precipitation extraction and analyzed using reversed phase HPLC with MS/MS detection. A linear calibration curve 1~500 ng/mL was created using 1/x weighted regression analysis for the quantitative determination of Irinotecan concentration in the plasma, and an 0.1~40 ng/mL linear calibration curve was created using 1/x weighted regression analysis to quantitatively determine Irinotecan M3 concentration in the plasma.
Based on the validation results, the quantitative analysis method could be ensured, in which the accuracy and reproducibility were in compliance with specifications. The validation analysis of Within-run and Between-run demonstrated that the precision and accuracy for LLOQ（Lower Limit of Quantification）was not deviate by more than 20.0% while those for other concentrations were within 15.0%. The stability test results of drugs in the plasma were also in compliance with specifications. So the quantitative analysis method could conform to the acceptance criteria for analysis of Irinotecan and its metabolites in biological samples.
Advisor Committee Dey-chyi Sheu - advisor
Files Date of Defense 2015-07-23 Date of Submission 2015-08-18